Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 464.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 125,678 shares of the biopharmaceutical company's stock after purchasing an additional 103,405 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.22% of Agios Pharmaceuticals worth $4,130,000 as of its most recent SEC filing.
A number of other institutional investors have also added to or reduced their stakes in AGIO. Erste Asset Management GmbH purchased a new stake in Agios Pharmaceuticals in the 3rd quarter worth about $97,199,000. Vestal Point Capital LP bought a new stake in shares of Agios Pharmaceuticals in the third quarter valued at approximately $33,767,000. State Street Corp lifted its stake in shares of Agios Pharmaceuticals by 10.2% during the 3rd quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company's stock valued at $103,586,000 after buying an additional 216,484 shares in the last quarter. Frazier Life Sciences Management L.P. boosted its holdings in Agios Pharmaceuticals by 19.7% in the 3rd quarter. Frazier Life Sciences Management L.P. now owns 1,044,154 shares of the biopharmaceutical company's stock worth $46,392,000 after buying an additional 172,180 shares during the period. Finally, Loomis Sayles & Co. L P grew its stake in Agios Pharmaceuticals by 36.4% in the 3rd quarter. Loomis Sayles & Co. L P now owns 612,366 shares of the biopharmaceutical company's stock valued at $27,208,000 after buying an additional 163,503 shares in the last quarter.
Agios Pharmaceuticals Stock Up 3.3 %
Shares of NASDAQ AGIO traded up $1.03 during trading hours on Thursday, reaching $32.71. 461,543 shares of the stock traded hands, compared to its average volume of 734,356. The company's 50-day simple moving average is $33.51 and its two-hundred day simple moving average is $41.49. The company has a market capitalization of $1.87 billion, a P/E ratio of 2.88 and a beta of 0.90. Agios Pharmaceuticals, Inc. has a 52-week low of $27.14 and a 52-week high of $62.58.
Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. As a group, sell-side analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
A number of research firms have recently commented on AGIO. StockNews.com lowered Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Friday, February 14th. HC Wainwright started coverage on Agios Pharmaceuticals in a report on Monday, February 24th. They set a "buy" rating and a $58.00 target price for the company. Scotiabank increased their price target on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a "sector outperform" rating in a report on Monday, December 9th. Cantor Fitzgerald restated an "overweight" rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. Finally, Royal Bank of Canada upped their target price on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an "outperform" rating in a report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Hold" and an average target price of $56.57.
Check Out Our Latest Analysis on AGIO
Insider Buying and Selling
In other news, insider Tsveta Milanova sold 2,804 shares of the stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $32.18, for a total transaction of $90,232.72. Following the completion of the sale, the insider now owns 18,906 shares of the company's stock, valued at approximately $608,395.08. This represents a 12.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.93% of the stock is owned by corporate insiders.
About Agios Pharmaceuticals
(
Free Report)
Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.
Featured Articles
Before you consider Agios Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agios Pharmaceuticals wasn't on the list.
While Agios Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
